Johns Hopkins Medicine researchers have shown that clusters of lab-grown brain tissue made from the cells of Alzheimer's patients can be used to gauge how those specific patients might respond to drugs commonly prescribed for the psychiatric symptoms of the disease. The work, funded in part by the National Institutes of Health, appeared April 8 in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
The tissue clusters, called organoids, are grown in the lab from a patient's own cells and behave enough like brain tissue to be studied directly. That matters because Alzheimer's, which affects more than 7 million Americans, does not progress or respond to medication the same way in everyone. If a patient's own cells can be used to test drugs outside the body, prescribing could eventually be matched to subgroups of patients rather than applied broadly and adjusted by trial and error.
The team also examined extracellular vesicles, tiny particles the organoids release. Those vesicles appear to carry cellular information that could point toward new biomarkers for diagnosing Alzheimer's and determining how far it has advanced - a persistent gap in clinical care, where staging often relies on indirect measures.
Study leader Vasiliki Machairaki, an associate professor of genetic medicine at the Johns Hopkins University School of Medicine, framed the findings as evidence that patient-derived organoids and their secreted vesicles can help stage the disease, probe the mechanisms driving it, and assess treatment responses across patient subgroups. The results add to a growing body of organoid research rather than settling it; the practical payoff would come only if these lab findings hold up as predictors of what happens in actual patients.